Underscored Lunit INSIGHT CXR's potential to empower clinicians in making accurate and timely decisions, improving both efficiency and patient outcomes in high-pressure clinical environments, addressing growing diagnostic demands in hospitals worldwide
"RSNA 2024's focus on AI in radiology aligns seamlessly with Lunit's mission to conquer cancer through AI," said Brandon Suh, CEO of Lunit. "The studies we're presenting this year exemplify how our AI solutions address real-world challenges—ensuring diagnostic equity in breast cancer detection and empowering clinicians with improved accuracy for critical chest X-ray findings. These innovations are about reshaping the standard of care for diverse patient populations globally. We are honored to contribute to this year's discussion on AI's role in radiology and look forward to sharing how Lunit is driving meaningful impact in the field."
The RSNA 2024 Annual Meeting will take place in Chicago, Illinois, from December 1-6, 2024. For more information, visit Lunit's booth #4929 in the AI Showcase.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 hospitals and medical institutions across 55+ countries.
Back to HCB News
